Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, CNBC’s Annika Kim Constantino reports. The drugmaker contends the medications are too complex for those manufacturers to make safely. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, CNBC notes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk (NYSE:NVO) Seeks Ban on Weight Loss Drug Copies
- Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data
- Novo Nordisk’s Ambitious Share Repurchase Strategy
- Novo Nordisk call volume above normal and directionally bullish
- Novo Nordisk price target lowered to $156 from $160 at BMO Capital